<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">PEN</journal-id>
<journal-id journal-id-type="hwp">sppen</journal-id>
<journal-id journal-id-type="nlm-ta">JPEN J Parenter Enteral Nutr</journal-id>
<journal-title>Journal of Parenteral and Enteral Nutrition</journal-title>
<issn pub-type="ppub">0148-6071</issn>
<issn pub-type="epub">1941-2444</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0148607112465653</article-id>
<article-id pub-id-type="publisher-id">10.1177_0148607112465653</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Invited Commentary</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Y-site Compatibility of Intravenous Drugs With Parenteral Nutrition</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Newton</surname><given-names>David W.</given-names></name>
<degrees>PhD, FAPhA</degrees>
</contrib>
<aff id="aff1-0148607112465653">Department of Biopharmaceutical Sciences, Bernard J. Dunn School of Pharmacy, Shenandoah University, Winchester, Virginia</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-0148607112465653">David W. Newton, PhD, FAPhA, Department of Biopharmaceutical Sciences, Bernard J. Dunn School of Pharmacy, Shenandoah University, 1775 North Sector Court, Winchester, Virginia 22601, USA. Email: <email>dnewton@su.edu</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>5</month>
<year>2013</year>
</pub-date>
<volume>37</volume>
<issue>3</issue>
<fpage>297</fpage>
<lpage>299</lpage>
<history>
<date date-type="received">
<day>17</day>
<month>9</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>3</day>
<month>10</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© 2012 American Society for Parenteral and Enteral Nutrition</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">The American Society for Parenteral and Enteral Nutrition</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<p>The seminal 1977 article on compatibility/incompatibility (C/I) of drugs injected in intravenous (IV) tubing Y-sites estimated a 1:1 volume mixture ratio from the Y-site to needle tip based on dye dilution measurement and evaluated 4-hour static samples microscopically.<sup><xref ref-type="bibr" rid="bibr1-0148607112465653">1</xref></sup> This issue of the <italic>Journal of Parenteral and Enteral Nutrition</italic> includes an article by Bouchoud and colleagues<sup><xref ref-type="bibr" rid="bibr2-0148607112465653">2</xref></sup> describing an advanced adaptation of that protocol on C/I of 25 drugs individually with parenteral nutrition (PN).</p>
<p>The duration from when drugs are injected into an IV infusion through a Y-site until vein entry is usually less than 1 minute, which allows for precipitation but not chemical degradation of drugs. Bouchoud and colleagues’ report<sup><xref ref-type="bibr" rid="bibr2-0148607112465653">2</xref></sup> of “phase separation” after 10 minutes in samples containing IV fat (lipid) emulsion and serum albumin affirms that zero time (T0) was, as in almost any study, greater than 0. This begs the question of whether or not a short time from true T0 until nominal T0 affects the results; it can with emulsion cracking or creaming and some precipitation.</p>
<p>The drugs in Bouchoud and colleagues’ report<sup><xref ref-type="bibr" rid="bibr2-0148607112465653">2</xref></sup> were not chemically assayed after mixing with PN, which is justified by few statistically significant and fewer clinically significant chemical degradation reactions of drugs in ≤4 hours in clinical dilutions. One possibility is the nonenzymatic Maillard reaction forming condensation products between the trace aldehyde form of dextrose and primary amino compounds.<sup><xref ref-type="bibr" rid="bibr3-0148607112465653">3</xref>,<xref ref-type="bibr" rid="bibr4-0148607112465653">4</xref></sup> In the nutrition world, this is the “browning reaction” of dextrose (and other reducing sugars) with amino acids and proteins, and it is also the source of hemoglobin A1c.<sup><xref ref-type="bibr" rid="bibr3-0148607112465653">3</xref></sup> Another possibility is secondary, tertiary, or quaternary structural denaturation of peptides (eg, monoclonal antibodies, cytokines, and enzymes), which should be prepared and administered strictly according to manufacturers’ instructions.</p>
<p>Precipitates in PN of some drugs whose molecules are small and lipophilic may not persist because of (1) drug diffusion into fat globules in IV fat emulsion in PN and (2) extravascular distribution from and solubilization via plasma protein binding in blood. Precipitation has long been described as physical or visual incompatibility, but precipitates result from acid-base and anion-cation chemical reactions and changes in intermolecular hydrogen bonding and similar van der Waals electrostatic forces.<sup><xref ref-type="bibr" rid="bibr5-0148607112465653">5</xref><xref ref-type="bibr" rid="bibr6-0148607112465653"/><xref ref-type="bibr" rid="bibr7-0148607112465653"/>-<xref ref-type="bibr" rid="bibr8-0148607112465653">8</xref></sup> Phase separation, breaking, or cracking of emulsions results chronologically from (1) increased interfacial tension between dispersed phase droplets and the continuous external phase (eg, fat globules and water in IV fat emulsion), which results from decreased emulsifying agent function (eg, chemical(s) reacting with egg phosphatides in IV fat emulsion), followed by (2) a transient increase in Gibbs or surface free energy, followed by (3) internal phase coalescence to minimize interfacial surface area, which (4) minimizes free energy that naturally seeks a minimum value.<sup><xref ref-type="bibr" rid="bibr9-0148607112465653">9</xref></sup></p>
<p>The samples containing IV fat emulsion in the report by Bouchard and colleagues<sup><xref ref-type="bibr" rid="bibr2-0148607112465653">2</xref></sup> were packaged in EVA (ethylene vinyl acetate) bags, but fat-free samples were packaged in glass bottles. Although a large majority of C/I results are the same in glass and plastic when all other conditions are the same, there are some clinically important differences attributable to drug adsorption and sorption, as well as plasticizer solvent leaching.<sup><xref ref-type="bibr" rid="bibr5-0148607112465653">5</xref>,<xref ref-type="bibr" rid="bibr6-0148607112465653">6</xref>,<xref ref-type="bibr" rid="bibr10-0148607112465653">10</xref></sup> Cracking or creaming of IV fat emulsion in PN formulations is always immediately dangerous but not always immediately visible, whereas small violations of PFAT5 (ie, &gt;0.05% of emulsified fat globules ≥5 µm<sup>10</sup>) are harmful after chronic exposure.</p>
<p>All precipitation is not visible, and all visible precipitation is neither instantaneous nor persistent. This sounds like Albert Einstein’s much wiser “Everything that can be counted does not necessarily count; everything that counts cannot necessarily be counted.” There are 3 main causes for some precipitates not being visible. First, human visual acuity suffers both inter- and intrapersonal variability; second, small size, transparency, or translucency of some crystals impairs observation; and third, precipitates may be obscured by concurrent ingredients, the prime example being white calcium monohydrogen phosphate, CaHPO<sub>4</sub>, in PN containing opaque white IV fat emulsion. Precipitation may not be evident or complete instantaneously, as evidenced by postfiltration crystal growth or Ostwald ripening of supersaturated CaHPO<sub>4</sub> in PN over 2 weeks and delayed appearance of phenytoin crystals in phenytoin sodium injection dilutions.<sup><xref ref-type="bibr" rid="bibr4-0148607112465653">4</xref>,<xref ref-type="bibr" rid="bibr7-0148607112465653">7</xref>,<xref ref-type="bibr" rid="bibr8-0148607112465653">8</xref>,<xref ref-type="bibr" rid="bibr11-0148607112465653">11</xref>,<xref ref-type="bibr" rid="bibr12-0148607112465653">12</xref></sup> When precipitates decrease or disappear over time, it is the result of either dissolution in nonsaturated final homogeneous concentrations after initial nonuniform concentration layering or undetected adherence of original or fewer larger particles to containers.</p>
<p>Apparent exact duplication of any well-designed and conducted drug C/I study may not yield identical results. The predominant causes for this potentially hazardous situation (ie, hazardous based on the presumption of compatibility in clinical formulations) are the following:</p>
<list id="list1-0148607112465653" list-type="order">
<list-item><p>Intrinsic variability in accuracy and precision of human performance and physical factors<list id="list2-0148607112465653" list-type="alpha-lower">
<list-item><p>Visual observations and instrumental analyses</p></list-item>
<list-item><p>Volume measurement of liquids</p></list-item>
<list-item><p>Temperature. Bouchard and colleagues2 report “room temperature” without numerical values. In most in vitro C/I studies, temperature is specified as a 1°–2° range with a mean in the low 20s (eg, 24 ± 2°C). To preclude assumption of some particular temperature mean or range, the United States Pharmacopeia (USP) defines room temperature as “the temperature prevailing in a working area.” USP controlled room temperature, however, ranges from 20°C–25°C, allows excursions between 15°C and 30°C, and spikes to 40°C not exceeding 24 hours and requires a mean kinetic temperature not greater than 25°C.10 Controlled room temperature, obviously, applies to extended storage of individual manufactured products, not to drug-PN mixtures. Exposure of drug-PN mixtures for 4 hours to a 15°C–40°C range while maintaining a kinetic mean of 25°C would produce different results than a 25 ± 2°C range. A seemingly negligible difference of 1°–2° can determine a result of total solubility vs precipitation for some solutes at saturation concentration at one end of that small range.</p></list-item>
<list-item><p>Agitation force and frequency or their absence</p></list-item></list></p></list-item>
<list-item><p>Permissible ranges of strengths of ingredients and pH in drug injections and drugs for injection (sterile powders to be dissolved with sterile solvents) in official compendia, such as the <italic>European Pharmacopeia</italic> and <italic>USP</italic>, and patent-protected U.S. Food and Drug Administration (FDA) new drug applications<sup><xref ref-type="bibr" rid="bibr7-0148607112465653">7</xref>,<xref ref-type="bibr" rid="bibr8-0148607112465653">8</xref></sup></p></list-item></list>
<p>The following are the most probable possible causes of instantaneous precipitation in mixtures of one drug in a PN of pH ≤6.5, which results mostly from a final 15%–30% concentration of mildly acidic dextrose injection.<sup><xref ref-type="bibr" rid="bibr4-0148607112465653">4</xref><xref ref-type="bibr" rid="bibr5-0148607112465653"/><xref ref-type="bibr" rid="bibr6-0148607112465653"/><xref ref-type="bibr" rid="bibr7-0148607112465653"/>-<xref ref-type="bibr" rid="bibr8-0148607112465653">8</xref>,<xref ref-type="bibr" rid="bibr11-0148607112465653">11</xref><xref ref-type="bibr" rid="bibr12-0148607112465653"/><xref ref-type="bibr" rid="bibr13-0148607112465653"/>-<xref ref-type="bibr" rid="bibr14-0148607112465653">14</xref></sup></p>
<list id="list3-0148607112465653" list-type="order">
<list-item><p>Calcium chloride or gluconate and potassium or sodium phosphates concentrations that result in CaHPO<sub>4</sub> exceeding solubility. From the equilibrium, H<sub>2</sub>PO<sub>4</sub><sup>−</sup> ↔ HPO<sub>4</sub><sup>2−</sup>, as pH decreases below the pK<sub>a</sub> of 7.2, the dihydrogen phosphate, H<sub>2</sub>PO<sub>4</sub><sup>−</sup>, is predominantly formed, which is good, and as pH increases above 7.2, the monohydrogen phosphate, HPO<sub>4</sub><sup>2−</sup>, is predominantly formed, which is bad. The water solubility of Ca(H<sub>2</sub>PO<sub>4</sub>)<sub>2</sub> is 18 mg/mL, but that of CaHPO<sub>4</sub> is only 0.3 mg/mL. The reactivity of Ca<sup>2+</sup> with HPO<sub>4</sub><sup>2−</sup> is decreased in PN by Ca<sup>2+</sup> binding with amino acids as it does with serum albumin in blood. The deaths of 2 patients in 1994 from CaHPO<sub>4</sub> in PN when calcium gluconate and potassium phosphates were mixed in less than 50% of final volume before the addition of acidic dextrose injection heralded the sequencing of phosphates early and calcium last.<sup><xref ref-type="bibr" rid="bibr11-0148607112465653">11</xref><xref ref-type="bibr" rid="bibr12-0148607112465653"/><xref ref-type="bibr" rid="bibr13-0148607112465653"/><xref ref-type="bibr" rid="bibr14-0148607112465653"/><xref ref-type="bibr" rid="bibr15-0148607112465653"/>-<xref ref-type="bibr" rid="bibr16-0148607112465653">16</xref></sup> In that tragedy, the initial CaHPO<sub>4</sub> crystals were invisible in the IV fat emulsion but may have dissolved given adequate agitation and time after the final PN volume was achieved and before being infused.<xref ref-type="fn" rid="fn1-0148607112465653">*</xref></p></list-item>
<list-item><p>Acid-base reactions between organic drug anions (bases) from their potassium or sodium salts and hydronium ions, H<sub>3</sub>O<sup>+</sup>, from PN. Decreasing pH increases the conjugate acid form of all organic weak electrolytes, as is defined by the Henderson-Hasselbalch equation, and in the case of drugs anions, the acid form is the less soluble nonionized form. For example, phenytoin nonionized acid precipitates sooner and more extensively in dextrose injection (pH range 3.2–6.5) than in sodium chloride injection (pH range 4.5–7.0) when phenytoin sodium injection is equally diluted in those IV solutions. Bouchoud et al<sup><xref ref-type="bibr" rid="bibr2-0148607112465653">2</xref></sup> reported precipitation of fluorouracil (5-FU) because of its alkaline pH. The <italic>USP</italic> nomenclature policy<sup><xref ref-type="bibr" rid="bibr9-0148607112465653">9</xref></sup> excludes names of nondrug ions (eg, sodium) in titles of injections when drug salts form in situ during dissolution. For example, furosemide injection <italic>USP</italic> consists of furosemide prepared with sodium hydroxide at a pH of 8.0–9.3, which makes furosemide ≥99.999% in its anionic base form (ie, it is an unnamed sodium salt). Drug injections with a low-end pH of 7.5 should be expected to be incompatible in acidic PN. Drugs dosed based on their active moiety are also not titled as their salts,<sup><xref ref-type="bibr" rid="bibr9-0148607112465653">9</xref></sup> although their injection forms are salts. For example, ampicillin for injection <italic>USP</italic> contains a mass of ampicillin sodium salt equivalent to the labeled strength of ampicillin, which means ampicillin is an anion, and gentamicin injection <italic>USP</italic> contains a mass of gentamicin sulfate equivalent to the labeled strength of gentamicin, which means gentamicin is a cation.</p></list-item>
<list-item><p>Besides HPO<sub>4</sub><sup>2−</sup>, calcium forms poorly soluble salts with most other divalent anions, for example, with ceftriaxone sodium, which is actually a disodium salt giving ceftriaxone a −2 valence. Increased pH from sodium bicarbonate could precipitate calcium carbonate, CaCO<sub>3</sub>.</p></list-item>
<list-item><p>Desolvation of nonionized hydrophobic drugs formulated in solutions containing &gt;10% by volume of alcohol <italic>USP</italic>, ethanol, polyethylene glycols 200–400, and propylene glycol when improperly diluted in aqueous fluids. The prototypic examples are diazepam and digoxin injections made with 10% alcohol and 40% propylene glycol.</p></list-item>
<list-item><p>Desolubilization of nonionized hydrophobic drugs formulated in colloidal surfactant micelle solutions (eg, amphotericin B, cyclosporine, and etoposide) when improperly diluted in aqueous fluids</p></list-item></list>
<p>The results of C/I exemplary studies such as that of Bouchoud and colleagues<sup><xref ref-type="bibr" rid="bibr2-0148607112465653">2</xref></sup> reinforce 4 practices that are vital to protecting patients. First, a sterile filter of appropriate nominal pore size should be aseptically affixed to all PN catheters downstream from Y-site injection ports. Second, visual inspection should determine C/I only when experience is lacking or clinical exigency precludes accessing a trustable reference source and performing instrumental analysis. Third, drugs should be injected into the flowing PN fluid via a Y-site, not into the PN bag. Fourth, only one drug at a time should be injected into a flowing PN, and no other drug should be added until at least 50 mL of additional PN has been infused.</p>
</body>
<back>
<fn-group>
<fn fn-type="other" id="fn1-0148607112465653">
<label>*</label>
<p>In 1996 and 1997, the author was a consultant on calcium-phosphates compatibility to the attorney for the families of the 2 deceased patients (ie, the plaintiffs).</p>
</fn>
<fn fn-type="financial-disclosure">
<p>Financial disclosure: none declared.</p>
</fn>
<fn fn-type="other">
<p>This article originally appeared online on October 31, 2012.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0148607112465653">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Allen</surname><given-names>LV</given-names></name>
<name><surname>Levinson</surname><given-names>RS</given-names></name>
<name><surname>Phisutsinthop</surname><given-names>D</given-names></name>
</person-group>. <article-title>Compatibility of various admixtures with secondary additives at Y-injection sites of intravenous administration sets</article-title>. <source>Am J Hosp Pharm</source>. <year>1977</year>;<volume>34</volume>:<fpage>939</fpage>-<lpage>943</lpage>.</citation>
</ref>
<ref id="bibr2-0148607112465653">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bouchoud</surname><given-names>L</given-names></name>
<name><surname>Fonzo-Christe</surname><given-names>C</given-names></name>
<name><surname>Klingmüller</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Compatibility of intravenous drugs with parenteral nutrition: in vitro evaluation</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2013</year>:<volume>37</volume>;<fpage>416</fpage>-<lpage>424</lpage>.</citation>
</ref>
<ref id="bibr3-0148607112465653">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Newton</surname><given-names>DW</given-names></name>
</person-group>. <article-title>Maillard reactions in pharmaceutical formulations and human health</article-title>. <source>Int J Pharm Comp</source>. <year>2011</year>;<volume>15</volume>:<fpage>32</fpage>-<lpage>40</lpage>.</citation>
</ref>
<ref id="bibr4-0148607112465653">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Newton</surname><given-names>DW</given-names></name>
</person-group>. <article-title>Drug compatibility and stability in dextrose <italic>vs</italic> saline</article-title>. <source>Int J Pharm Comp</source>. <year>2011</year>;<volume>15</volume>:<fpage>190</fpage>-<lpage>192</lpage>.</citation>
</ref>
<ref id="bibr5-0148607112465653">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Newton</surname><given-names>DW</given-names></name>
</person-group>. <article-title>Physicochemical determinants of incompatibility and instability in injectable drug solutions and admixtures</article-title>. <source>Am J Hosp Pharm</source>. <year>1978</year>;<volume>35</volume>:<fpage>1213</fpage>-<lpage>1222</lpage>.</citation>
</ref>
<ref id="bibr6-0148607112465653">
<label>6.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Newton</surname><given-names>DW</given-names></name>
</person-group>. <article-title>Physicochemical determinants of incompatibility and instability of drugs for injection and infusion</article-title>. In: <person-group person-group-type="editor">
<name><surname>Trissel</surname><given-names>LA</given-names></name>
</person-group>, ed. <source>Handbook on Injectable Drugs</source>. <edition>3rd ed.</edition> <publisher-loc>Bethesda, MD</publisher-loc>: <publisher-name>American Society of Hospital Pharmacists</publisher-name>; <year>1983</year>:<fpage>xi</fpage>-<lpage>xxi</lpage>.</citation>
</ref>
<ref id="bibr7-0148607112465653">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Newton</surname><given-names>DW</given-names></name>
</person-group>. <article-title>Drug incompatibility chemistry</article-title>. <source>Am J Health Syst Pharm</source>. <year>2009</year>;<volume>66</volume>:<fpage>348</fpage>-<lpage>357</lpage>; <year>1431</year>.</citation>
</ref>
<ref id="bibr8-0148607112465653">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Newton</surname><given-names>DW</given-names></name>
</person-group>. <article-title>General guidelines/summary for compatibility (solubility) and chemical stability</article-title>. <source>Sci Technol Hosp Pharm</source>. <year>2012</year>;<volume>2</volume>(<issue>2</issue>).</citation>
</ref>
<ref id="bibr9-0148607112465653">
<label>9.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Allen</surname><given-names>LV</given-names></name>
<name><surname>Popovich</surname><given-names>NG</given-names></name>
<name><surname>Ansel</surname><given-names>HC</given-names></name>
</person-group>. <source>Ansel’s Pharmaceutical Dosage Forms and Delivery Systems</source>. <edition>9th ed.</edition> <publisher-loc>Baltimore, MD</publisher-loc>: <publisher-name>Lippincott Williams &amp; Wilkins</publisher-name>; <volume>2011</volume>:<fpage>397</fpage>.</citation>
</ref>
<ref id="bibr10-0148607112465653">
<label>10.</label>
<citation citation-type="book">
<collab>U.S. Pharmacopeial Convention, Inc</collab>. <article-title>General notices, general chapter &lt;729&gt; globule size distribution in lipid injectable emulsions, general chapter &lt;1121&gt; nomenclature, and general chapter &lt;1150&gt; pharmaceutical stability</article-title>. In: <source>The United States Pharmacopeia 35th Revision and The National Formulary</source> <edition>30th Edition</edition>. <publisher-loc>Rockville, MD</publisher-loc>: <publisher-name>United States Pharmacopeial Convention</publisher-name>; <year>2012</year>:<volume>11</volume>, <fpage>310</fpage>-<lpage>312</lpage>, <fpage>725</fpage>-<lpage>728</lpage>; <fpage>763</fpage>-<lpage>765</lpage>.</citation>
</ref>
<ref id="bibr11-0148607112465653">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Newton</surname><given-names>DW</given-names></name>
<name><surname>Driscoll</surname><given-names>DF</given-names></name>
</person-group>. <article-title>Calcium and phosphates compatibility: revisited again</article-title>. <source>Am J Health Syst Pharm</source>. <year>2008</year>;<volume>65</volume>:<fpage>73</fpage>-<lpage>80</lpage>.</citation>
</ref>
<ref id="bibr12-0148607112465653">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fausel</surname><given-names>CA</given-names></name>
<name><surname>Newton</surname><given-names>DW</given-names></name>
<name><surname>Driscoll</surname><given-names>DF</given-names></name><etal/>
</person-group>. <article-title>Effect of fat emulsion and supersaturation on calcium phosphate solubility in parenteral nutrient admixtures</article-title>. <source>Int J Pharm Comp</source>. <year>1997</year>;<volume>1</volume>:<fpage>54</fpage>-<lpage>59</lpage>.</citation>
</ref>
<ref id="bibr13-0148607112465653">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Driscoll</surname><given-names>DF</given-names></name>
<name><surname>Newton</surname><given-names>DW</given-names></name>
<name><surname>Bistrian</surname><given-names>BR</given-names></name>
</person-group>. <article-title>Potential hazards of precipitation associated with calcium chloride in parenteral nutrition admixtures: response to Migaki et al</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2012</year>;<volume>36</volume>:<fpage>497</fpage>-<lpage>498</lpage>.</citation>
</ref>
<ref id="bibr14-0148607112465653">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Newton</surname><given-names>DW</given-names></name>
</person-group>. <article-title>Crux of drug compatibility and incompatibility</article-title>. <source>Am J Health Syst Pharm</source>. <year>2010</year>;<volume>67</volume>:<fpage>108</fpage>-<lpage>112</lpage>.</citation>
</ref>
<ref id="bibr15-0148607112465653">
<label>15.</label>
<citation citation-type="journal">
<collab>Food and Drug Administration</collab>. <article-title>Safety alert: hazards of precipitation associated with parenteral nutrition</article-title>. <source>Am J Hosp Pharm</source>. <year>1994</year>;<volume>51</volume>:<fpage>1427</fpage>-<lpage>1428</lpage>.</citation>
</ref>
<ref id="bibr16-0148607112465653">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hill</surname><given-names>SF</given-names></name>
<name><surname>Heldman</surname><given-names>LS</given-names></name>
<name><surname>Goo</surname><given-names>EDH</given-names></name><etal/>
</person-group>. <article-title>Fatal microvascular pulmonary emboli from precipitation of a total nutrient admixture solution</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>1996</year>;<volume>20</volume>:<fpage>81</fpage>-<lpage>87</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>